OLEZARSEN SODIUM - Generic Drug Details

What are the generic drug sources for olezarsen sodium and what is the scope of patent protection?

Olezarsen sodium is the generic ingredient in one branded drug marketed by Ionis Pharms Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olezarsen sodium has three hundred and twenty patent family members in forty countries.

One supplier is listed for this compound.

Summary for OLEZARSEN SODIUM

International Patents:	320
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLEZARSEN SODIUM
What excipients (inactive ingredients) are in OLEZARSEN SODIUM?	OLEZARSEN SODIUM excipients list
DailyMed Link:	OLEZARSEN SODIUM at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OLEZARSEN SODIUM

Constraining patent/regulatory exclusivity:

ADJUNCT TO DIET TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for OLEZARSEN SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes				Y
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes				Y
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes				Y
Ionis Pharms Inc	TRYNGOLZA (AUTOINJECTOR)	olezarsen sodium	SOLUTION;SUBCUTANEOUS	218614-001	Dec 19, 2024		RX	Yes	Yes

International Patents for OLEZARSEN SODIUM

Country	Patent Number	Title	Estimated Expiration
Japan	2017008059	アポリポタンパク質ＣＩＩＩ（ＡＰＯＣＩＩＩ）発現の調節 (MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION)
Russian Federation	2686080	КОМПОЗИЦИИ И СПОСОБЫ (COMPOSITIONS AND METHODS)
South Korea	20150118180	지질단백질 리파제 결핍 (LPLD) 모집단에서 아포지질단백질 C-III (APOCIII) 발현의 조절 (MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS)
Russian Federation	2018136140	КОМПОЗИЦИИ И СПОСОБЫ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HBV И TTR
Israel	275246	מודולציה של ביטוי אפוליפופרוטאין c-iii (apociii) באוכלוסיות בעלות מחסור בליפופרוטאין ליפאז (lpld) (Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations)

Supplementary Protection Certificates for OLEZARSEN SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	28/2025	Austria		PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307
3524680	CA 2025 00027	Denmark		PRODUCT NAME: EPLONTERSEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1875 20250307
2991656	CA 2026 00003	Denmark		PRODUCT NAME: OLEZARSEN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/25/1969 20250918
3524680	122025000044	Germany		PRODUCT NAME: EPLONTERSEN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 20250306
2991656	C20260001	Finland

Market Dynamics and Financial Trajectory for Olezarsen Sodium

Last updated: February 20, 2026

What is Olezarsen Sodium?

Olezarsen sodium is an antisense oligonucleotide developed to target specific gene expressions linked to lipid metabolism. It is currently under clinical evaluation for familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by elevated triglycerides. The drug is being developed by Ionis Pharmaceuticals, with collaboration partners in specialty and rare disease markets.

Market Overview

Target Indications and Market Size

• Primary use: Familial chylomicronemia syndrome (FCS)
• Prevalence: Estimated at 1-2 per million population globally; roughly 5,000-10,000 patients worldwide
• Secondary potential: Severe hypertriglyceridemia associated with other metabolic conditions
• Market potential: Due to the rarity of FCS, the primary market remains niche; however, expanded use in hypertriglyceridemia could broaden reach

Competitive Landscape

• Lead competitors: Drug candidates from companies like Regeneron (omics like evinacumab), Novo Nordisk (synthetic peptides for lipid control), and traditional triglyceride-lowering therapies (fibrates, niacin)
• Unique positioning: Olezarsen's antisense mechanism offers targeted inhibition of apolipoprotein C-III (ApoC-III), a key regulator of triglycerides

Regulatory and Development Timeline

• Initial clinical trials (Phase 1-2): Completed by 2022
• Phase 3 trials: Initiated in 2022, completion expected by 2024
• Potential approval: Anticipated around 2025, contingent on trial outcomes

Regulatory Pathway

• Orphan drug designation obtained in multiple regions
• Fast-track and breakthrough therapy designation requested based on preliminary efficacy data

Financial Trajectory

R&D Investment and Costs

• Investment: Estimated $100 million accumulated over preclinical and phase 1-2 trials (per Ionis filings)
• Cost structure: Includes laboratory research, clinical trial management, regulatory submission, manufacturing scalability

Revenue Projections

• Pricing: Estimated at $350,000-$500,000 annually per patient, reflecting its orphan drug status
• Market penetration assumptions: 20-30% of diagnosed patients by 2030
• Projected sales:
  • Year 2025: $50-150 million, limited by early approval
  • Year 2030: $2-3 billion, assuming wider approvals for hypertriglyceridemia

Profitability Outlook

• High fixed R&D costs, with low initial revenue
• Break-even not expected before 2027 due to development timelines and low patient volumes
• Long-term profitability depends on expanded indications and payer acceptance

Key Financial Factors Influencing Growth

• Pricing power: Enhanced by rare disease status and lack of direct competition
• Reimbursement challenge: Payers’ willingness to fund high-cost therapies for rare conditions
• Regulatory hurdles: Efficacy signals and safety profiles determine accelerated approval likelihood
• Strategic partnerships: Collaborations with pharmaceutical and biotech firms for commercialization

Risks and Opportunities

Risks	Opportunities
Clinical trial failures	Expansion into broader hypertriglyceridemia markets
Regulatory delays or rejections	Orphan drug status offers market exclusivity up to 7 years in the US
Payer resistance to high-cost drugs	Potential for combination therapies with existing lipid-lowering agents
Competitive threats from gene-editing approaches	Growing focus on personalized medicine in lipid disorders

Market Entry and Commercial Strategy

• Market access: Enrolling reimbursement agreements with specialty insurers
• Patient identification: Collaborations with genetics clinics and rare disease networks
• Manufacturing: Investment in scalable synthesis to meet future demand

Conclusion

Olezarsen sodium exhibits a promising but narrowly targeted market trajectory centered on familial chylomicronemia syndrome. Financial success hinges on regulatory progress, pricing dynamics, and the potential to expand into broader hypertriglyceridemia treatments. The company's strategic focus on rare diseases grants exclusivity benefits that buoy long-term revenue prospects.

Key Takeaways

• Market size for familial chylomicronemia syndrome remains limited; expansion into hypertriglyceridemia is critical.
• R&D investments are substantial, with a projected breakeven around 2027.
• Pricing strategies leverage orphan drug status, with potential revenues reaching several billion dollars by 2030.
• Regulatory pathways are favorable due to orphan designations, but approval depends on continued clinical success.
• Market access challenges require strategic payer negotiations and patient identification programs.

FAQs

1. What are the main challenges in commercializing Olezarsen sodium?
Achieving regulatory approval based on clinical trial data and securing payer reimbursement for high-cost treatment remain primary challenges.

2. How does Olezarsen sodium compare with existing lipid-lowering treatments?
It offers targeted gene suppression of ApoC-III, delivering potentially more effective triglyceride reduction in genetically predisposed patients, especially in severe cases unresponsive to standard therapies.

3. What is the potential for expanding the drug’s indications?
The drug could extend its use to other severe hypertriglyceridemia conditions, provided clinical data supports safety and efficacy in broader populations.

4. How does orphan drug status influence the financial outlook?
It grants market exclusivity for up to 7 years in the US, reduces development costs via incentives, and improves valuation prospects.

5. What are the key variables affecting long-term revenue?
Market uptake, pricing negotiations, reimbursement policies, and clinical success in later-stage trials will shape revenue growth.

---

References

[1] Ionis Pharmaceuticals. (2022). Clinical Trial Updates.
[2] FDA. (2022). Orphan Drug Designations and Approvals.
[3] Global Markets Insights. (2023). Hypertriglyceridemia Therapeutics Market.
[4] IQVIA. (2023). Rare Disease Market Trends.
[5] MarketWatch. (2023). Rare Disease Drug Pricing Analysis.